Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals.

Mimuro J, Mizukami H, Shima M, Matsushita T, Taki M, Muto S, Higasa S, Sakai M, Ohmori T, Madoiwa S, Ozawa K, Sakata Y.

J Med Virol. 2014 Nov;86(11):1990-7. doi: 10.1002/jmv.23818.

PMID:
24136735
2.

Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.

Li C, Narkbunnam N, Samulski RJ, Asokan A, Hu G, Jacobson LJ, Manco-Johnson MJ, Monahan PE; Joint Outcome Study Investigators..

Gene Ther. 2012 Mar;19(3):288-94. doi: 10.1038/gt.2011.90.

PMID:
21697954
3.

The prevalence of neutralizing antibodies against AAV serotype 1 in healthy subjects in China: implications for gene therapy and vaccines using AAV1 vector.

Liu Q, Huang W, Zhao C, Zhang L, Meng S, Gao D, Wang Y.

J Med Virol. 2013 Sep;85(9):1550-6. doi: 10.1002/jmv.23647.

PMID:
23852678
4.

Adeno-associated virus antibody profiles in newborns, children, and adolescents.

Calcedo R, Morizono H, Wang L, McCarter R, He J, Jones D, Batshaw ML, Wilson JM.

Clin Vaccine Immunol. 2011 Sep;18(9):1586-8. doi: 10.1128/CVI.05107-11.

5.

Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia.

Harrington EA, Sloan JL, Manoli I, Chandler RJ, Schneider M, McGuire PJ, Calcedo R, Wilson JM, Venditti CP.

Hum Gene Ther. 2016 May;27(5):345-53. doi: 10.1089/hum.2015.092.

PMID:
26790480
6.

Prevalence of neutralizing antibodies against liver-tropic adeno-associated virus serotype vectors in 100 healthy Chinese and its potential relation to body constitutions.

Ling C, Wang Y, Feng YL, Zhang YN, Li J, Hu XR, Wang LN, Zhong MF, Zhai XF, Zolotukhin I, Srivastava A, Ling CQ.

J Integr Med. 2015 Sep;13(5):341-6. doi: 10.1016/S2095-4964(15)60200-X.

PMID:
26343106
7.

Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors.

Liu Q, Huang W, Zhang H, Wang Y, Zhao J, Song A, Xie H, Zhao C, Gao D, Wang Y.

Gene Ther. 2014 Aug;21(8):732-8. doi: 10.1038/gt.2014.47.

PMID:
24849042
8.

Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice.

Scallan CD, Jiang H, Liu T, Patarroyo-White S, Sommer JM, Zhou S, Couto LB, Pierce GF.

Blood. 2006 Mar 1;107(5):1810-7.

9.

Reduced prevalence of serum antibodies against adeno-associated virus type 2 in patients with adult T-cell leukaemia lymphoma.

Walz CM, Nakamura M, Fukunaga T, Jasiewicz Y, Edler L, Schlehofer JR, Tanaka Y.

J Med Virol. 2001 Sep;65(1):185-9.

PMID:
11505462
10.

Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM.

J Infect Dis. 2009 Feb 1;199(3):381-90. doi: 10.1086/595830.

PMID:
19133809
11.

Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.

Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, Masurier C.

Hum Gene Ther. 2010 Jun;21(6):704-12. doi: 10.1089/hum.2009.182.

PMID:
20095819
12.

Neutralizing antibodies against adeno-associated viruses in inflammatory bowel disease patients: implications for gene therapy.

van der Marel S, Comijn EM, Verspaget HW, van Deventer S, van den Brink GR, Petry H, Hommes DW, Ferreira V.

Inflamm Bowel Dis. 2011 Dec;17(12):2436-42. doi: 10.1002/ibd.21673.

PMID:
21370319
13.
14.

Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV).

Erles K, Sebökovà P, Schlehofer JR.

J Med Virol. 1999 Nov;59(3):406-11.

PMID:
10502275
15.
16.

Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates.

Kotterman MA, Yin L, Strazzeri JM, Flannery JG, Merigan WH, Schaffer DV.

Gene Ther. 2015 Feb;22(2):116-26. doi: 10.1038/gt.2014.115.

17.

Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models.

Rapti K, Louis-Jeune V, Kohlbrenner E, Ishikawa K, Ladage D, Zolotukhin S, Hajjar RJ, Weber T.

Mol Ther. 2012 Jan;20(1):73-83. doi: 10.1038/mt.2011.177.

19.

Preexisting Neutralizing Antibodies to Adeno-Associated Virus Capsids in Large Animals Other Than Monkeys May Confound In Vivo Gene Therapy Studies.

Calcedo R, Franco J, Qin Q, Richardson DW, Mason JB, Boyd S, Wilson JM.

Hum Gene Ther Methods. 2015 Jun;26(3):103-5. doi: 10.1089/hgtb.2015.082.

20.

Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines.

Lin J, Calcedo R, Vandenberghe LH, Figueredo JM, Wilson JM.

Hum Gene Ther. 2008 Jul;19(7):663-9. doi: 10.1089/hum.2008.033.

Supplemental Content

Support Center